Literature DB >> 18759347

Predictors of progression in patients with Friedreich ataxia.

Alison La Pean1, Neal Jeffries, Chelsea Grow, Bernard Ravina, Nicholas A Di Prospero.   

Abstract

Friedreich ataxia is an inherited, progressive, neurodegenerative disorder that is clinically heterogeneous. It is caused by a trinucleotide (GAA) repeat expansion resulting in frataxin loss and oxidative stress. We assessed clinical features including the development of cardiomyopathy and scoliosis and disease progression including loss of ambulation and interference with activities of daily living relative to the length of the GAA repeat, age of onset, and age of diagnosis in a retrospective cohort study of 61 genetically confirmed patients. The use of antioxidants such as vitamins, dietary supplements, and idebenone was also examined. Linear regression and Cox proportional hazard models assessed predictors to disease milestones. The shorter GAA allele accounted for part of the variability in the age of diagnosis (46%) and less in the age of onset (27%). Multivariate analysis demonstrated that age at diagnosis, which may incorporate other genetic and environmental factors, is more important than GAA length in predicting cardiomyopathy, scoliosis, and disease progression. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759347      PMCID: PMC2579318          DOI: 10.1002/mds.22248

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  Clinical description and roentgenologic evaluation of patients with Friedreich's ataxia.

Authors:  G Geoffroy; A Barbeau; G Breton; B Lemieux; M Aube; C Leger; J P Bouchard
Journal:  Can J Neurol Sci       Date:  1976-11       Impact factor: 2.104

2.  Expanded GAA repeats and clinical variation in Friedreich's ataxia.

Authors:  I Mateo; J Llorca; V Volpini; J Corral; J Berciano; O Combarros
Journal:  Acta Neurol Scand       Date:  2004-01       Impact factor: 3.209

3.  Antioxidant use in Friedreich ataxia.

Authors:  Lauren Myers; Jennifer M Farmer; Robert B Wilson; Lisa Friedman; Amy Tsou; Susan L Perlman; Sub H Subramony; Christopher M Gomez; Tetsuo Ashizawa; George R Wilmot; Katherine D Mathews; Laura J Balcer; David R Lynch
Journal:  J Neurol Sci       Date:  2007-11-07       Impact factor: 3.181

4.  Clinical and genetic study of Friedreich ataxia in an Australian population.

Authors:  M B Delatycki; D B Paris; R J Gardner; G A Nicholson; N Nassif; E Storey; J C MacMillan; V Collins; R Williamson; S M Forrest
Journal:  Am J Med Genet       Date:  1999-11-19

5.  Genotype and phenotype analysis of Friedreich's ataxia compound heterozygous patients.

Authors:  M De Castro; J García-Planells; E Monrós; J Cañizares; R Vázquez-Manrique; J J Vílchez; M Urtasun; M Lucas; G Navarro; G Izquierdo; M D Moltó; F Palau
Journal:  Hum Genet       Date:  2000-01       Impact factor: 4.132

6.  Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features.

Authors:  A E Harding
Journal:  Brain       Date:  1981-09       Impact factor: 13.501

Review 7.  Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.

Authors:  J M Cooper; A H V Schapira
Journal:  Biofactors       Date:  2003       Impact factor: 6.113

Review 8.  Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.

Authors:  R Lodi; B Rajagopalan; J L Bradley; D J Taylor; J G Crilley; P E Hart; A M Blamire; D Manners; P Styles; A H V Schapira; J M Cooper
Journal:  Free Radic Res       Date:  2002-04

9.  The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia.

Authors:  A Filla; G De Michele; F Cavalcanti; L Pianese; A Monticelli; G Campanella; S Cocozza
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

10.  Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion.

Authors:  V Campuzano; L Montermini; M D Moltò; L Pianese; M Cossée; F Cavalcanti; E Monros; F Rodius; F Duclos; A Monticelli; F Zara; J Cañizares; H Koutnikova; S I Bidichandani; C Gellera; A Brice; P Trouillas; G De Michele; A Filla; R De Frutos; F Palau; P I Patel; S Di Donato; J L Mandel; S Cocozza; M Koenig; M Pandolfo
Journal:  Science       Date:  1996-03-08       Impact factor: 47.728

View more
  11 in total

1.  A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype.

Authors:  Marguerite V Evans-Galea; Louise A Corben; Justin Hasell; Charles A Galea; Michael C Fahey; Desirée du Sart; Martin B Delatycki
Journal:  Neurogenetics       Date:  2011-08-10       Impact factor: 2.660

Review 2.  Inherited neuropathies: clinical overview and update.

Authors:  Christopher J Klein; Xiaohui Duan; Michael E Shy
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

3.  Sensitivity of spatiotemporal gait parameters in measuring disease severity in Friedreich ataxia.

Authors:  Sarah C Milne; Darren R Hocking; Nellie Georgiou-Karistianis; Anna Murphy; Martin B Delatycki; Louise A Corben
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

4.  Current and emerging treatment options in the management of Friedreich ataxia.

Authors:  Michelangelo Mancuso; Daniele Orsucci; Anna Choub; Gabriele Siciliano
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

5.  Dysphagia and swallowing-related quality of life in Friedreich ataxia.

Authors:  Adam P Vogel; Sophie E Brown; Joanne E Folker; Louise A Corben; Martin B Delatycki
Journal:  J Neurol       Date:  2013-12-27       Impact factor: 4.849

6.  Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort.

Authors:  Christian Rummey; John M Flynn; Louise A Corben; Martin B Delatycki; George Wilmot; Sub H Subramony; Khalaf Bushara; Antoine Duquette; Christopher M Gomez; J Chad Hoyle; Richard Roxburgh; Lauren Seeberger; Grace Yoon; Katherine D Mathews; Theresa Zesiewicz; Susan Perlman; David R Lynch
Journal:  Ann Clin Transl Neurol       Date:  2021-05-05       Impact factor: 4.511

Review 7.  Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes.

Authors:  Lisa Mosconi; Valentina Berti; Russell H Swerdlow; Alberto Pupi; Ranjan Duara; Mony de Leon
Journal:  Hum Genomics       Date:  2010-02       Impact factor: 4.639

8.  Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone.

Authors:  Shaila D Ghanekar; Wai Wai Miller; Colin J Meyer; Kevin J Fenelon; Alvin Lacdao; Theresa A Zesiewicz
Journal:  Degener Neurol Neuromuscul Dis       Date:  2019-10-15

9.  Predictors of loss of ambulation in Friedreich's ataxia.

Authors:  Christian Rummey; Jennifer M Farmer; David R Lynch
Journal:  EClinicalMedicine       Date:  2020-01-08

10.  Impact of diabetes in the Friedreich ataxia clinical outcome measures study.

Authors:  Ashley McCormick; Jennifer Farmer; Susan Perlman; Martin Delatycki; George Wilmot; Katherine Matthews; Grace Yoon; Chad Hoyle; Sub H Subramony; Theresa Zesiewicz; David R Lynch; Shana E McCormack
Journal:  Ann Clin Transl Neurol       Date:  2017-07-26       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.